MFW
ACAD icon

Mosaic Family Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

Mosaic Family Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-55
Closed -$2K – 680
2017
Q3 		$2K Buy
+55
New +$1.79K ﹤0.01% 820

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mosaic Family Wealth's ACAD Position: Q4 2017 in Review

Mosaic Family Wealth sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 55 shares — an estimated $2K sold.

Mosaic Family Wealth first reported a position in ACAD in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

  • Mosaic Family Wealth reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Mosaic Family Wealth sold 55 Acadia Pharmaceuticals shares in Q4 2017, an estimated $2K.
  • Mosaic Family Wealth first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Mosaic Family Wealth's Acadia Pharmaceuticals position peaked at $2K in Q3 2017.
  • 210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on Mosaic Family Wealth's 13F filing for Q4 2017, filed 13 Feb 2018.